Q3 EPS Forecast for Heron Therapeutics Lowered by Analyst

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Equities research analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for shares of Heron Therapeutics in a note issued to investors on Tuesday, August 11th. HC Wainwright analyst B. Folkes now anticipates that the biotechnology company will post earnings per share of ($0.03) for the quarter, down from their previous forecast of ($0.02). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.09) per share. HC Wainwright also issued estimates for Heron Therapeutics’ Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.14) EPS, FY2027 earnings at ($0.12) EPS, FY2028 earnings at ($0.06) EPS, FY2029 earnings at ($0.01) EPS and FY2030 earnings at $0.01 EPS.

Several other research analysts have also issued reports on HRTX. Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Friday, July 17th. Wall Street Zen upgraded shares of Heron Therapeutics to a “sell” rating in a research report on Saturday, August 8th. Finally, Needham & Company LLC downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 2nd. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Heron Therapeutics currently has an average rating of “Hold” and a consensus price target of $2.00.

Heron Therapeutics Stock Performance

Shares of HRTX stock opened at $0.34 on Thursday. The business’s 50 day simple moving average is $0.44 and its 200 day simple moving average is $0.81. Heron Therapeutics has a one year low of $0.30 and a one year high of $1.57. The stock has a market capitalization of $64.53 million, a PE ratio of -1.79 and a beta of 1.65. The company has a debt-to-equity ratio of 17.51, a current ratio of 2.53 and a quick ratio of 1.51.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Monday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter. Heron Therapeutics had a negative return on equity of 265.11% and a negative net margin of 22.52%.The company had revenue of $37.67 million for the quarter, compared to analyst estimates of $42.19 million.

Hedge Funds Weigh In On Heron Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Rubric Capital Management LP lifted its position in shares of Heron Therapeutics by 3.3% during the 4th quarter. Rubric Capital Management LP now owns 30,046,828 shares of the biotechnology company’s stock valued at $39,061,000 after buying an additional 946,100 shares during the last quarter. Clearline Capital LP increased its stake in shares of Heron Therapeutics by 26.0% in the fourth quarter. Clearline Capital LP now owns 12,235,239 shares of the biotechnology company’s stock worth $15,906,000 after purchasing an additional 2,522,712 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in shares of Heron Therapeutics by 9.2% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 11,185,325 shares of the biotechnology company’s stock valued at $14,541,000 after purchasing an additional 946,100 shares during the period. BlackRock Inc. bought a new position in Heron Therapeutics in the 2nd quarter worth approximately $4,503,000. Finally, Orbimed Advisors LLC purchased a new position in Heron Therapeutics in the 1st quarter valued at approximately $7,855,000. 80.01% of the stock is owned by institutional investors.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.